Clinical Trials | An Interventional Phase 3, Double-Blind, Randomized Study To Evaluate Efficacy And Safety Of PF-08634404 In Combination With Chemotherapy Versus Pembrolizumab In Combination With Chemotherapy In Adult Participants With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with locally advanced or metastatic non-small cell lung cancer that are not a candidate for complete surgical resection or curative concurrent/sequential chemoradiotherapy. The purpose of this study is to learn about the safety and effects of PF-08634404 + chemotherapy compared to pembrolizumab + chemotherapy. The study drug, PF-08634404, is an investigational drug. That means it is not approved by the U.S. Food and Drug Administration (FDA). In this study, you will be assigned by chance (like the flip of a coin) to receive the study drug PF-08634404 and chemotherapy, or the comparator drug pembrolizumab and chemotherapy. You will have a 50% (1 in 2) chance of receiving the study drug PF-08634404, and a 50% (1 in 2) chance of receiving the comparator drug pembrolizumab. All participants will receive chemotherapy (in combination with PF-08634404 or pembrolizumab). Taking part in this study may have some risks and discomforts. The study drug(s) or test(s) may make you feel unwell or uncomfortable or could harm you. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. Your time in the study will depend on how long you take the study drug(s) and have follow-up visits. You will take the study drugs for approximately 2 years or until you or your doctor decides you should stop. This might be because your scans show that your cancer is getting worse, the study drug is no longer helping, you have bad side effects, or you wish to stop taking the study drug. Additional information found here: Study Details | NCT07222566 | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ClinicalTrials.gov For questions, contact: [email protected]